Journal article

YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia

Fiona C Brownfoot, Stephen Tong, Natalie J Hannan, Roxanne Hastie, Ping Cannon, Laura Tuohey, Tu'uhevaha J Kaitu'u-Lino

Molecular and Cellular Endocrinology | ELSEVIER IRELAND LTD | Published : 2015

Abstract

Preeclampsia is a serious complication of pregnancy with no medical treatment. It is caused by intermittent placental hypoxia and release of sFlt-1 and soluble endoglin, leading to wide spread maternal endothelial dysfunction and multisystem organ injury. YC-1 is a guanylyl cyclase activator and HIF1α inhibitor developed for use in hypertension and atherosclerosis. We examined whether YC-1 reduces sFlt-1 and sENG secretion and reverses endothelial dysfunction in primary human tissues. YC-1 significantly reduced sFlt-1 and sENG secretion from human umbilical vein endothelial cells, purified primary trophoblast cells and placental explants taken from patients with preterm preeclampsia. This wa..

View full abstract

Grants

Awarded by National Health and Medical Research Council of Australia (NHMRC)


Awarded by NHMRC


Funding Acknowledgements

This work was funded by The National Health and Medical Research Council of Australia (NHMRC; #1048707, #1046484) and an Arthur Wilson RANZCOG scholarship. FB was supported by an Australian Postgraduate Award and an AVANT scholarship. The NHMRC provided salary support (#1050765 to ST #1062418 to TKL, #628927 to NJH). The funders had no role in study design, data collection, analysis, decision to publish or helped to prepare the manuscript.